The DOI matches its Crossref record.
THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY: 2 PREDICTIVE VALUE OF THE EARLY CLINICAL COURSE
Abstract
Controversy exists regarding the predictive value of the early clinical course of multiple sclerosis (MS). Three parameters often considered are the attack rate, the first interattack interval and the rate at which disability develops in the early years of the disease. We have recorded the time to reach successive levels of disability defined by the Kurtzke Disability Status Scale (DSS) in 1,099 MS patients followed at University Hospital, London, Canada between 1972 and 1984. Our population is particularly suitable because of its size, the high degree of ascertainment of cases in the community, and the regular follow-up provided. Life table analysis was used to compare survival in patients stratified according to the above three parameters using DSS 6 as end point. Significant differences were evident in the survival distributions. Despite the extensive interindividual variation in the rate at which disability developed, the early course of MS may be useful in determining the relative risk of rapid progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Self-citationCompston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Self-citationConfavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 996
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., Muraro, P. A., Daumer, M., & Ebers, G. C. (2010) · Brain · doi:10.1093/brain/awq118 · Cited by 711
Self-citationRandomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O’Connor, P., Monaghan, E., Li, D., & Weinshenker, B. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 635
Self-citationBerger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022328 · Cited by 616
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Le Page, E., Coustans, M., Laplaud, D., Oger, J., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 596
Miller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
Defining high, medium, and low impact prognostic factors for developing multiple sclerosis
Tintore, M., Rovira, À., Río, J., Otero-Romero, S., Arrambide, G., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., Negrotto, L., et al. (2015) · Brain · doi:10.1093/brain/awv105 · Cited by 530
Age at disability milestones in multiple sclerosis
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awh714 · Cited by 525
The epidemiology of multiple sclerosis
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802973-2.00011-2 · Cited by 514
Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G., Waldmann, H., et al. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Silent progression in disease activity–free relapsing multiple sclerosis
University of California, S. F. M. T., Cree, B. A. C., Hollenbach, J. A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., Zhu, A. H., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 465
Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis
Gorman, M. P., Healy, B. C., Polgar-Turcsanyi, M., & Chitnis, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.505 · Cited by 454
Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C. (2006) · Brain · doi:10.1093/brain/awh721 · Cited by 447
Self-citationProspective study on the relationship between infections and multiple sclerosis exacerbations
Buljevac, D., Flach, H. Z., Hop, W. C. J., Hijdra, D., Laman, J. D., Savelkoul, H. F. J., van der Meché, F. G. A., van Doorn, P. A., & Hintzen, R. Q. (2002) · Brain · doi:10.1093/brain/awf098 · Cited by 427
Effect of relapses on development of residual deficit in multiple sclerosis
Lublin, F. D., Baier, M., & Cutter, G. (2003) · Neurology · doi:10.1212/01.wnl.0000096175.39831.21 · Cited by 421
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Kappos, L., Bates, D., Hartung, H.-P., Havrdova, E., Miller, D., Polman, C. H., Ravnborg, M., Hauser, S. L., Rudick, R. A., Weiner, H. L., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70078-9 · Cited by 421
Natural history of multiple sclerosis
Weinshenker, B. G. (1994) · Annals of Neurology · doi:10.1002/ana.410360704 · Cited by 405
Self-citationClinical Course of Multiple Sclerosis
Klineova, S., & Lublin, F. D. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028928 · Cited by 401
Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis
Campbell, G. R., Ziabreva, I., Reeve, A. K., Krishnan, K. J., Reynolds, R., Howell, O., Lassmann, H., Turnbull, D. M., & Mahad, D. J. (2011) · Annals of Neurology · doi:10.1002/ana.22109 · Cited by 386
Course and prognosis in early-onset MS: Comparison with adult-onset forms
Simone, I. L., Carrara, D., Tortorella, C., Liguori, M., Lepore, V., Pellegrini, F., Bellacosa, A., Ceccarelli, A., Pavone, I., & Livrea, P. (2002) · Neurology · doi:10.1212/01.wnl.0000036907.37650.8e · Cited by 343
Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients
Río, J., Nos, C., Tintoré, M., Téllez, N., Galán, I., Pelayo, R., Comabella, M., & Montalban, X. (2006) · Annals of Neurology · doi:10.1002/ana.20740 · Cited by 327
Fingolimod for Multiple Sclerosis
Pelletier, D., & Hafler, D. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmct1101691 · Cited by 315
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
Kieseier, B. C. (2011) · CNS Drugs · doi:10.2165/11591110-000000000-00000 · Cited by 308
Epidemiology of Multiple Sclerosis: A Critical Overview
Sadovnick, A. D., & Ebers, G. C. (1993) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100047351 · Cited by 304
Self-citationDalton, C. M., Brex, P. A., Miszkiel, K. A., Hickman, S. J., MacManus, D. G., Plant, G. T., Thompson, A. J., & Miller, D. H. (2002) · Annals of Neurology · doi:10.1002/ana.10240 · Cited by 290
Multidisciplinary rehabilitation for adults with multiple sclerosis
Khan, F., Turner-Stokes, L., Ng, L., Kilpatrick, T., & Amatya, B. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006036.pub2 · Cited by 286
Progress in determining the causes and treatment of multiple sclerosis
Noseworthy, J. H. (1999) · Nature · doi:10.1038/399a040 · Cited by 278
Self-citationThe Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics
Minden, S. L., Frankel, D., Hadden, L., Perloff, J., Srinath, K. P., & Hoaglin, D. C. (2006) · Multiple Sclerosis Journal · doi:10.1191/135248506ms1262oa · Cited by 272
New perspectives in the natural history of multiple sclerosis
Tremlett, H., Zhao, Y., Rieckmann, P., & Hutchinson, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e3973f · Cited by 261
Chitnis, T., Glanz, B., Jaffin, S., & Healy, B. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458508101933 · Cited by 260
Epidemiology and natural history of multiple sclerosis: new insights
Kantarci, O., & Wingerchuk, D. (2006) · Current Opinion in Neurology · doi:10.1097/01.wco.0000227033.47458.82 · Cited by 156
Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis
Sucksdorff, M., Matilainen, M., Tuisku, J., Polvinen, E., Vuorimaa, A., Rokka, J., Nylund, M., Rissanen, E., & Airas, L. (2020) · Brain · doi:10.1093/brain/awaa275 · Cited by 142
Early MRI in optic neuritis: The risk for disability
Swanton, J. K., Fernando, K. T., Dalton, C. M., Miszkiel, K. A., Altmann, D. R., Plant, G. T., Thompson, A. J., & Miller, D. H. (2009) · Neurology · doi:10.1212/01.wnl.0000341935.41852.82 · Cited by 94
Tallantyre, E. C., Bo, L., Al-Rawashdeh, O., Owens, T., Polman, C. H., Lowe, J., & Evangelou, N. (2009) · Brain · doi:10.1093/brain/awp106 · Cited by 93
Tintore, M., Cobo-Calvo, A., Carbonell, P., Arrambide, G., Otero-Romero, S., Río, J., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012726 · Cited by 90
Early predictors of conversion to secondary progressive multiple sclerosis
Barzegar, M., Najdaghi, S., Afshari-Safavi, A., Nehzat, N., Mirmosayyeb, O., & Shaygannejad, V. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103115 · Cited by 52
Self-reported levels of education and disability progression in multiple sclerosis
D'hooghe, M. B., Haentjens, P., Van Remoortel, A., De Keyser, J., & Nagels, G. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12555 · Cited by 35
MS, MRI, and the 2010 McDonald criteria: A Canadian expert commentary
Selchen, D., Bhan, V., Blevins, G., Devonshire, V., Duquette, P., Grand’Maison, F., Kremenchutzky, M., Lapierre, Y., Li, D., von Riedemann, S. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318277d144 · Cited by 25
The initial course of daily functioning in multiple sclerosis: a three-year follow-up study
de Groot, V, Beckerman, H., Lankhorst, G. J., Polman, C. H., & Bouter, L. M. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1238oa · Cited by 23
Metadata
- Authors
- WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1989
- Volume
- 112
- Issue
- 6
- Pages
- 1419-1428
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2704729794
- Cited by
- 602
- References
- 0
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.